Finally, network pharmacology analysis revealed that MAPK1 is one of the key targets associated with both T2DM and AD, reflecting the shared pathological mechanisms between these pathologies (Wang et al. 2021). The gene discussed is MAPK1; the disease is Alzheimer disease.